268 related articles for article (PubMed ID: 23899616)
21. Lack of correlation between in vitro susceptibility to Benznidazole and phylogenetic diversity of Trypanosoma cruzi, the agent of Chagas disease.
Villarreal D; Barnabé C; Sereno D; Tibayrenc M
Exp Parasitol; 2004; 108(1-2):24-31. PubMed ID: 15491545
[TBL] [Abstract][Full Text] [Related]
22. Diterpenoid alkaloid derivatives as potential chemotherapeutic agents in American trypanosomiasis.
González P; Marín C; Rodríguez-González I; Illana A; Mateo H; Longoni SS; Rosales MJ; González-Coloma A; Reina M; Sánchez-Moreno M
Pharmacology; 2006; 76(3):123-8. PubMed ID: 16391494
[TBL] [Abstract][Full Text] [Related]
23. Indazoles: a new top seed structure in the search of efficient drugs against Trypanosoma cruzi.
Aguilera-Venegas B; Olea-Azar C; Arán VJ; Speisky H
Future Med Chem; 2013 Oct; 5(15):1843-59. PubMed ID: 24144415
[TBL] [Abstract][Full Text] [Related]
24. Further insights into biological evaluation of new anti-Trypanosoma cruzi 5-nitroindazoles.
Fonseca-Berzal C; Escario JA; Arán VJ; Gómez-Barrio A
Parasitol Res; 2014 Mar; 113(3):1049-56. PubMed ID: 24435615
[TBL] [Abstract][Full Text] [Related]
25. In vitro and in vivo trypanocidal activity of the ethyl esters of N-allyl and N-propyl oxamates using different Trypanosoma cruzi strains.
Aguirre-Alvarado C; Zaragoza-Martínez F; Rodríguez-Páez L; Nogueda B; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2007 Apr; 22(2):227-33. PubMed ID: 17518350
[TBL] [Abstract][Full Text] [Related]
26. A quinoxaline derivative as a potent chemotherapeutic agent, alone or in combination with benznidazole, against Trypanosoma cruzi.
Rodrigues JH; Ueda-Nakamura T; Corrêa AG; Sangi DP; Nakamura CV
PLoS One; 2014; 9(1):e85706. PubMed ID: 24465654
[TBL] [Abstract][Full Text] [Related]
27. Biological characterization of a beta-galactosidase expressing clone of Trypanosoma cruzi CL strain.
Le-Senne A; Muelas-Serrano S; Fernández-Portillo C; Escario JA; Gómez-Barrio A
Mem Inst Oswaldo Cruz; 2002 Dec; 97(8):1101-5. PubMed ID: 12563473
[TBL] [Abstract][Full Text] [Related]
28. A new pharmacological screening assay with Trypanosoma cruzi epimastigotes expressing beta-galactosidase.
Vega C; Rolón M; Martínez-Fernández AR; Escario JA; Gómez-Barrio A
Parasitol Res; 2005 Mar; 95(4):296-8. PubMed ID: 15682334
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effects of parthenolide and benznidazole on Trypanosoma cruzi.
Pelizzaro-Rocha KJ; Tiuman TS; Izumi E; Ueda-Nakamura T; Dias Filho BP; Nakamura CV
Phytomedicine; 2010 Dec; 18(1):36-9. PubMed ID: 21035317
[TBL] [Abstract][Full Text] [Related]
30. 5-Nitroindazole-based compounds: further studies for activity optimization as anti-Trypanosoma cruzi agents.
Fonseca-Berzal C; Ibáñez-Escribano A; de Castro S; Escario JA; Gómez-Barrio A; Arán VJ
Acta Trop; 2022 Oct; 234():106607. PubMed ID: 35907502
[TBL] [Abstract][Full Text] [Related]
31. An in vitro iron superoxide dismutase inhibitor decreases the parasitemia levels of Trypanosoma cruzi in BALB/c mouse model during acute phase.
Olmo F; Urbanová K; Rosales MJ; Martín-Escolano R; Sánchez-Moreno M; Marín C
Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):110-6. PubMed ID: 26236582
[TBL] [Abstract][Full Text] [Related]
32. Experimental models in Chagas disease: a review of the methodologies applied for screening compounds against Trypanosoma cruzi.
Fonseca-Berzal C; Arán VJ; Escario JA; Gómez-Barrio A
Parasitol Res; 2018 Nov; 117(11):3367-3380. PubMed ID: 30232605
[TBL] [Abstract][Full Text] [Related]
33. Preparation and antitrypanosomal activity of secochiliolide acid derivatives.
Siless GE; Lozano E; Sánchez M; Mazzuca M; Sosa MA; Palermo JA
Bioorg Med Chem Lett; 2013 Sep; 23(17):4964-7. PubMed ID: 23910983
[TBL] [Abstract][Full Text] [Related]
34. New potent 5-nitroindazole derivatives as inhibitors of Trypanosoma cruzi growth: synthesis, biological evaluation, and mechanism of action studies.
Rodríguez J; Arán VJ; Boiani L; Olea-Azar C; Lavaggi ML; González M; Cerecetto H; Maya JD; Carrasco-Pozo C; Cosoy HS
Bioorg Med Chem; 2009 Dec; 17(24):8186-96. PubMed ID: 19900812
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of quinones derived from natural product komaroviquinone as anti-Trypanosoma cruzi agents.
Suto Y; Nakajima-Shimada J; Yamagiwa N; Onizuka Y; Iwasaki G
Bioorg Med Chem Lett; 2015 Aug; 25(15):2967-71. PubMed ID: 26037321
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antichagasic properties of new 1,2,6-thiadiazin-3,5-dione 1,1-dioxides and related compounds.
Di Maio R; Cerecetto H; Seoane G; Ochoa C; Arán VJ; Pérez E; Gómez Barrio A; Muelas S
Arzneimittelforschung; 1999 Sep; 49(9):759-63. PubMed ID: 10514904
[TBL] [Abstract][Full Text] [Related]
37. Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole.
Lamas MC; Villaggi L; Nocito I; Bassani G; Leonardi D; Pascutti F; Serra E; Salomón CJ
Int J Pharm; 2006 Jan; 307(2):239-43. PubMed ID: 16293378
[TBL] [Abstract][Full Text] [Related]
38. Trypanosoma cruzi: acute and long-term infection in the vertebrate host can modify the response to benznidazole.
Caldas S; Santos FM; de Lana M; Diniz LF; Machado-Coelho GL; Veloso VM; Bahia MT
Exp Parasitol; 2008 Mar; 118(3):315-23. PubMed ID: 17945216
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of novel benznidazole solutions during the experimental infection with Trypanosoma cruzi.
Manarin R; Lamas MC; Bottasso E; Serra E; Revelli S; Salomón CJ
Parasitol Int; 2013 Feb; 62(1):79-81. PubMed ID: 22975280
[TBL] [Abstract][Full Text] [Related]
40. Trypanosoma cruzi: Immunological predictors of benznidazole efficacy during experimental infection.
Fernández MC; González Cappa SM; Solana ME
Exp Parasitol; 2010 Feb; 124(2):172-80. PubMed ID: 19747482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
